文献速递临床免疫临床生化

S100B蛋白测定:bioMérieux Vidas® 3分析仪上新原型的评估

Measurement of S100B protein: evaluation of a new prototype on a bioMérieux Vidas® 3 analyzer.
PubMed 文献 · Clin Chem Lab Med · 2019-01-01

该研究评估了bioMérieux Vidas® 3分析仪上血清S100B蛋白测定原型的分析性能,包括血清与血浆的基质效应及不同温度储存稳定性,并与Roche Diagnostics系统进行比较,同时对80例因轻度创伤性脑损伤(mTBI)转诊至急诊的患者进行临床诊断性能比较,确认了S100B在mTBI管理中的阴性预测价值。

要点

  • bioMérieux Vidas® 3上S100B原型验证了血清基质及2-8°C、-20°C、-80°C储存稳定性。
  • 与Roche Diagnostics系统比较,分析精密度良好。
  • 80例mTBI急诊患者中确认了S100B的阴性预测价值。

核心结论

  • bioMérieux Vidas® 3分析仪上血清S100B测定的研究数据有助于解读该分析仪的S100B结果。

研究设计与样本

  • 评估血清和血浆的基质效应及在2-8°C、-20°C和-80°C储存后的稳定性。
  • 将bioMérieux新测定原型与Roche Diagnostics已建立的方法进行比较,并进行精密度研究。
  • 对80例因mTBI转诊至急诊的患者比较bioMérieux与Roche Diagnostics方法的临床诊断性能。

主要发现

  • 证实了2-8°C、-20°C和-80°C储存后的稳定性及血清基质的验证。
  • bioMérieux分析仪与Roche Diagnostics系统比较,分析精密度有效。
  • 临床诊断性能评估确认了S100B在mTBI管理中的阴性预测价值。

临床怎么用

  • 该研究数据可用于解读bioMérieux Vidas® 3分析仪上的血清S100B结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Background The addition of S100B protein to guidelines for the management of mild traumatic brain injury (mTBI) decreases the amount of unnecessary computed tomography (CT) scans with a significant decrease in radiation exposure and an increase in cost savings. Both DiaSorin and Roche Diagnostics have developed automated assays for S100B determination. Recently, bioMérieux developed a prototype immunoassay for serum S100B determination. For the first time, we present the evaluation of the S100B measurement using a bioMérieux Vidas® 3 analyzer. Methods We evaluated the matrix effects of serum and plasma, and their stability after storage at 2-8 °C, -20 °C and -80 °C. The new measurement prototype (bioMérieux) was compared with an established one (Roche Diagnostics), and a precision study was also conducted. Lastly, clinical diagnostics performance of the bioMérieux and Roche Diagnostics methods were compared for 80 patients referred to the Emergency Department for mTBI. Results Stability after storage at 2-8 °C, -20 °C, and -80 °C and validation of the serum matrix were demonstrated. The bioMérieux analyzer was compared to the Roche Diagnostics system, and the analytical precision was found to be efficient. Clinical diagnosis performance evaluation confirmed the predictive negative value of S100B in the management of mTBI. Conclusions The study's data are useful for interpreting serum S100B results on a bioMérieux Vidas® 3 analyzer.

来源:Clin Chem Lab Med,查看原文。版权归原作者所有。

引用

  1. Oris C, Chabanne R, Durif J, et al. Measurement of S100B protein: evaluation of a new prototype on a bioMérieux Vidas® 3 analyzer. Clin Chem Lab Med. 2019. PMID: 30763262. doi:10.1515/cclm-2018-1217

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。